U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07563829) titled 'NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies' on March 30.
Brief Summary: NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7.
In this research study we are:
* Evaluating the safety and possible effectiveness of NPX372.
* Identifying a safe and tolerable dose or doses for further study.
Participants who are treated will receive an intraven...